To access the live and archived webcast, visit the News & Events page of the company’s website at https://recludixpharma.com/news-events. The archived webcast will be available for 30 days following ...

LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...

One potentially serious complication of obstructive sleep apnea (OSA) is pulmonary hypertension (PH). Based on previous research that revealed involvement of perivascular immune and inflammatory ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and marketing partnership. The collaboration is aimed at increasing the ...

As for KT-621, the once-daily oral degrader of STAT6 protein is set to undergo a Phase 1b trial for atopic dermatitis (AD) in Q1, with data expected in Q4 2025. Phase 2b trials for KT-621 in AD ...

Gilead has inked a deal to li­cense Leo Phar­ma’s port­fo­lio of oral STAT6 can­di­dates for in­flam­ma­to­ry dis­eases, less than a month af­ter John­son & John­son … ...

Driven inflammatory disorders like asthma, chronic obstructive pulmonary disease, and atopic dermatitis, the cooperation centers on STAT6, a transcription factor associated with IL-4 and IL-13 ...

Gilead agreed to terms on a strategic partnership with LEO Pharma to accelerate the development and commercialization of STAT6, LEO’s small molecule oral program for treating patients with ...

STAT6 is a transcription factor essential for IL-4 and IL-13 cytokine signalling, which are validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis. Credit: ...